89bio Inc Stock Performance
| ETNB Stock | USD 8.96 0.20 2.28% |
The firm shows a Beta (market volatility) of 2.87, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 89bio will likely underperform. 89bio Inc at this time shows a risk of 4.07%. Please confirm 89bio Inc sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to decide if 89bio Inc will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days 89bio Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 89bio is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 6.74 | Five Day Return 15.86 | Year To Date Return (17.18) | Ten Year Return (55.05) | All Time Return (55.05) |
1 | Disposition of 16527 shares by Rohan Palekar of 89bio at 18.95 subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 5352 shares by Le-nguyen Quoc of 89bio at 8.46 subject to Rule 16b-3 | 09/09/2024 |
3 | Health Check How Prudently Does 89bio Use Debt | 09/26/2024 |
4 | Disposition of 9671 shares by Mansbach Harry H of 89bio at 11.53 subject to Rule 16b-3 | 09/27/2024 |
5 | Renaissance Technologies LLC Invests 2.24 Million in 89bio, Inc. - MarketBeat | 10/03/2024 |
6 | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 10/11/2024 |
7 | Acquisition by Le-nguyen Quoc of 8334 shares of 89bio subject to Rule 16b-3 | 10/14/2024 |
8 | 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at AASLD The Liver Meeting 2024 | 10/15/2024 |
9 | Disposition of 27955 shares by Le-nguyen Quoc of 89bio at 8.12 subject to Rule 16b-3 | 10/30/2024 |
10 | 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates | 11/07/2024 |
11 | 89bio, Inc. Announces Upsized Pricing of 125.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 11/13/2024 |
12 | 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Li... | 11/15/2024 |
13 | 89Bio Inc. Reports Q3 2024 Financial Results - TipRanks | 11/20/2024 |
| Begin Period Cash Flow | 55.3 M | |
| Free Cash Flow | -129.2 M |
89bio |
89bio Relative Risk vs. Return Landscape
If you would invest 914.00 in 89bio Inc on August 27, 2024 and sell it today you would lose (18.00) from holding 89bio Inc or give up 1.97% of portfolio value over 90 days. 89bio Inc is currently generating 0.0487% in daily expected returns and assumes 4.0732% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than 89bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
89bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 89bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 89bio Inc, and traders can use it to determine the average amount a 89bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ETNB |
Estimated Market Risk
| 4.07 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average 89bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 89bio by adding 89bio to a well-diversified portfolio.
89bio Fundamentals Growth
89bio Stock prices reflect investors' perceptions of the future prospects and financial health of 89bio, and 89bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 89bio Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 643.81 M | ||||
| Shares Outstanding | 117.58 M | ||||
| Price To Earning | (1.04) X | ||||
| Price To Book | 2.72 X | ||||
| EBITDA | (134.46 M) | ||||
| Net Income | (142.19 M) | ||||
| Cash And Equivalents | 193.34 M | ||||
| Cash Per Share | 4.16 X | ||||
| Total Debt | 27.11 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.81 X | ||||
| Book Value Per Share | 3.56 X | ||||
| Cash Flow From Operations | (129.19 M) | ||||
| Earnings Per Share | (2.96) X | ||||
| Market Capitalization | 1.03 B | ||||
| Total Asset | 596.27 M | ||||
| Retained Earnings | (457.43 M) | ||||
| Working Capital | 563.92 M | ||||
| Current Asset | 10.12 M | ||||
| Current Liabilities | 3.89 M | ||||
About 89bio Performance
By analyzing 89bio's fundamental ratios, stakeholders can gain valuable insights into 89bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if 89bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if 89bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.27) | (0.28) |
Things to note about 89bio Inc performance evaluation
Checking the ongoing alerts about 89bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 89bio Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 89bio Inc had very high historical volatility over the last 90 days | |
| Net Loss for the year was (142.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| 89bio Inc currently holds about 193.34 M in cash with (129.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.16. | |
| 89bio Inc has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: 89Bio Inc. Reports Q3 2024 Financial Results - TipRanks |
- Analyzing 89bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 89bio's stock is overvalued or undervalued compared to its peers.
- Examining 89bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 89bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of 89bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 89bio's stock. These opinions can provide insight into 89bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 89bio Stock analysis
When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |